Tariff treatment of products of uncooperative major drug producing or drug-transit countries

Subject to subsection (b), for every major drug producing country and every major drug-transit country, the President shall, on or after March 1, 1987, and March 1 of each succeeding year, to the extent considered necessary by the President to achieve the purposes of this subchapter— Subject to paragraph (3), subsection (a) shall not apply with respect to a country if the President determines and certifies to the Congress, at the time of the submission of the report required by section 2291h of title 22, that— during the previous year the country has cooperated fully with the United States, or has taken adequate steps on its own— A bilateral narcotics agreement referred to in subparagraph (A)(i)(I) is an agreement between the United States and a foreign country in which the foreign country agrees to take specific activities, including, where applicable, efforts to— If the President makes a certification with respect to a country pursuant to subparagraph (A)(ii), he shall include in such certification— In determining whether to make the certification required by paragraph (1) with respect to a country, the President shall consider the following: Has that government taken the legal and law enforcement steps necessary to eliminate, to the maximum extent possible, the laundering in that country of drug-related profits or drug-related moneys, as evidenced by— If the President takes action under subsection (a), that action shall remain in effect until— For the purpose of expediting the consideration and enactment of joint resolutions under paragraphs (3) and (4)— The action taken by the President under paragraph (1), (2), or (3) of subsection (a) shall apply to the products of a foreign country that are entered, or withdrawn from warehouse for consumption, during the period that such action is in effect. For each calendar year, the Secretary of State, after consultation with the appropriate committees of the Congress, shall establish numerical standards and other guidelines for determining which countries will be considered to be major drug-transit countries under section 2495(3)(A) and (B) of this title.